Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Papageorgiou SG, Vasilatou D, Kontos CK, Foukas P, Kefala M, Ioannidou ED, Bouchla A, Bazani E, Dimitriadis G, Pappa V. Treatment with 5-Azacytidine improves clinical outcome in high-risk MDS patients in the 'real life' setting: A single center observational study. ACTA ACUST UNITED AC 2015. [PMID: 26218077 DOI: 10.1179/1607845415y.0000000039] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]

For:	Papageorgiou SG, Vasilatou D, Kontos CK, Foukas P, Kefala M, Ioannidou ED, Bouchla A, Bazani E, Dimitriadis G, Pappa V. Treatment with 5-Azacytidine improves clinical outcome in high-risk MDS patients in the 'real life' setting: A single center observational study. ACTA ACUST UNITED AC 2015. [PMID: 26218077 DOI: 10.1179/1607845415y.0000000039] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]

Number

Cited by Other Article(s)

Haumschild R, Kennerly-Shah J, Barbarotta L, Zeidan AM. Clinical activity, pharmacokinetics, and pharmacodynamics of oral hypomethylating agents for myelodysplastic syndromes/neoplasms and acute myeloid leukemia: A multidisciplinary review. J Oncol Pharm Pract 2024;30:721-736. [PMID: 38509812 PMCID: PMC11118786 DOI: 10.1177/10781552241238979] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2023] [Revised: 02/23/2024] [Accepted: 02/23/2024] [Indexed: 03/22/2024]

Nannya Y, Tobiasson M, Sato S, Bernard E, Ohtake S, Takeda J, Creignou M, Zhao L, Kusakabe M, Shibata Y, Nakamura N, Watanabe M, Hiramoto N, Shiozawa Y, Shiraishi Y, Tanaka H, Yoshida K, Kakiuchi N, Makishima H, Nakagawa M, Usuki K, Watanabe M, Imada K, Handa H, Taguchi M, Kiguchi T, Ohyashiki K, Ishikawa T, Takaori-Kondo A, Tsurumi H, Kasahara S, Chiba S, Naoe T, Miyano S, Papaemanuil E, Miyazaki Y, Hellström-Lindberg E, Ogawa S. Postazacitidine clone size predicts long-term outcome of patients with myelodysplastic syndromes and related myeloid neoplasms. Blood Adv 2023;7:3624-3636. [PMID: 36989067 PMCID: PMC10365941 DOI: 10.1182/bloodadvances.2022009564] [Citation(s) in RCA: 11] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2022] [Revised: 01/09/2023] [Accepted: 01/12/2023] [Indexed: 03/30/2023] Open

Affiliation(s)

Yasuhito Nannya Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan Division of Hematopoietic Disease Control, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
Magnus Tobiasson Department of Medicine, Center for Hematology and Regenerative Medicine, Karolinska Institute, Stockholm, Sweden Division of Hematology, Department of Medicine, Karolinska University Hospital, Stockholm, Sweden
Shinya Sato Department of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan Japan Adult Leukemia Study Group, Japan
Elsa Bernard Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY
Shigeki Ohtake Kanazawa University, Kanazawa, Japan
June Takeda Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
Maria Creignou Department of Medicine, Center for Hematology and Regenerative Medicine, Karolinska Institute, Stockholm, Sweden Division of Hematology, Department of Medicine, Karolinska University Hospital, Stockholm, Sweden
Lanying Zhao Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
Manabu Kusakabe Department of Hematology, University of Tsukuba, Tsukuba, Japan
Yuhei Shibata Department of Hematology, Gifu Municipal Hospital, Gifu, Japan
Nobuhiko Nakamura Department of Hematology & Infectious Disease, Gifu University Hospital, Gifu, Japan
Mizuki Watanabe Department of Hematology and Oncology, Kyoto University, Kyoto, Japan
Nobuhiro Hiramoto Department of Hematology, Kobe City Medical Center General Hospital, Hyogo, Japan
Yusuke Shiozawa Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
Yuichi Shiraishi Division of Cellular Signaling, National Cancer Center Research Institute, Tokyo, Japan
Hiroko Tanaka Department of Integrated Data Science, M&D Data Science Center, Tokyo Medical and Dental University, Tokyo, Japan
Kenichi Yoshida Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
Nobuyuki Kakiuchi Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
Hideki Makishima Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
Masahiro Nakagawa Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
Kensuke Usuki Department of Hematology, NTT Medical Center Tokyo, Tokyo, Japan
Mitsumasa Watanabe Department of Hematology, Hyogo Prefectural Amagasaki General Medical Center, Hyogo, Japan
Kazunori Imada Department of Hematology, Japan Red Cross Osaka Hospital, Osaka, Japan
Hiroshi Handa Department of Hematology, Gunma University, Gunma, Japan
Masataka Taguchi Department of Hematology, Sasebo City General Hospital, Nagasaki, Japan
Toru Kiguchi Department of Hematology, Chugoku Central Hospital, Hiroshima, Japan
Kazuma Ohyashiki Department of Hematology, Tokyo Medical University, Tokyo, Japan
Takayuki Ishikawa Department of Hematology, Kobe City Medical Center General Hospital, Hyogo, Japan
Akifumi Takaori-Kondo Department of Hematology and Oncology, Kyoto University, Kyoto, Japan
Hisashi Tsurumi Department of Hematology & Infectious Disease, Gifu University Hospital, Gifu, Japan
Senji Kasahara Department of Hematology, Gifu Municipal Hospital, Gifu, Japan
Shigeru Chiba Department of Hematology, University of Tsukuba, Tsukuba, Japan
Tomoki Naoe Japan Adult Leukemia Study Group, Japan Nagoya Medical Center, Aichi, Japan
Satoru Miyano Department of Integrated Data Science, M&D Data Science Center, Tokyo Medical and Dental University, Tokyo, Japan
Elli Papaemanuil Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY
Yasushi Miyazaki Department of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan Japan Adult Leukemia Study Group, Japan
Eva Hellström-Lindberg Department of Medicine, Center for Hematology and Regenerative Medicine, Karolinska Institute, Stockholm, Sweden Division of Hematology, Department of Medicine, Karolinska University Hospital, Stockholm, Sweden
Seishi Ogawa Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan Department of Medicine, Center for Hematology and Regenerative Medicine, Karolinska Institute, Stockholm, Sweden Institute for the Advanced Study of Human Biology, Kyoto University, Kyoto, Japan

Collapse

Bouwstra R, van Meerten T, Bremer E. CD47‐SIRPα blocking‐based immunotherapy: Current and prospective therapeutic strategies. Clin Transl Med 2022;12:e943. [PMID: 35908284 PMCID: PMC9339239 DOI: 10.1002/ctm2.943] [Citation(s) in RCA: 29] [Impact Index Per Article: 14.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2022] [Revised: 05/31/2022] [Accepted: 06/07/2022] [Indexed: 01/22/2023] Open

Leisch M, Pfeilstöcker M, Stauder R, Heibl S, Sill H, Girschikofsky M, Stampfl-Mattersberger M, Tinchon C, Hartmann B, Petzer A, Schreder M, Kiesl D, Vallet S, Egle A, Melchardt T, Piringer G, Zebisch A, Machherndl-Spandl S, Wolf D, Keil F, Drost M, Greil R, Pleyer L. Adverse Events in 1406 Patients Receiving 13,780 Cycles of Azacitidine within the Austrian Registry of Hypomethylating Agents-A Prospective Cohort Study of the AGMT Study-Group. Cancers (Basel) 2022;14:cancers14102459. [PMID: 35626063 PMCID: PMC9140081 DOI: 10.3390/cancers14102459] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2022] [Revised: 04/27/2022] [Accepted: 05/05/2022] [Indexed: 11/16/2022] Open

Abstract

Simple Summary

Azacitidine is thus far the only drug shown to prolong overall survival and is, therefore, the recommended (backbone) treatment in patients diagnosed with myelodysplastic syndromes, chronic myelomonocytic leukemia and acute myeloid leukemia who are not eligible for intensive chemotherapy. Detailed reports on adverse events are often lacking. We performed a thorough analysis of the adverse events that occur during treatment with azacitidine in the largest cohort of patients treated with this drug published so far. We also compared the frequency of adverse events documented in our cohort to published data from randomized clinical trials with an azacitidine monotherapy arm. Adverse event documentation in the Austrian Registry was high. Hematologic adverse events occurred at a similar rate compared to published trials, whereas gastrointestinal toxicities were significantly less commonly reported. Our data complement results from clinical trials with real-world evidence and form a reference for future combination strategies with azacitidine.

Abstract

Background: Azacitidine is the treatment backbone for patients with acute myeloid leukemia, myelodysplastic syndromes and chronic myelomonocytic leukemia who are considered unfit for intensive chemotherapy. Detailed reports on adverse events in a real-world setting are lacking. Aims: To analyze the frequency of adverse events in the Austrian Registry of Hypomethylating agents. To compare real-world data with that of published randomized clinical trials. Results: A total of 1406 patients uniformly treated with a total of 13,780 cycles of azacitidine were analyzed. Hematologic adverse events were the most common adverse events (grade 3–4 anemia 43.4%, grade 3–4 thrombopenia 36.8%, grade 3–4 neutropenia 36.1%). Grade 3–4 anemia was significantly more common in the Registry compared to published trials. Febrile neutropenia occurred in 33.4% of patients and was also more common in the Registry than in published reports. Other commonly reported adverse events included fatigue (33.4%), pain (29.2%), pyrexia (23.5%), and injection site reactions (23.2%). Treatment termination due to an adverse event was rare (5.1%). Conclusion: The safety profile of azacitidine in clinical trials is reproducible in a real-world setting. With the use of prophylactic and concomitant medications, adverse events can be mitigated and azacitidine can be safely administered to almost all patients with few treatment discontinuations.

Collapse

Affiliation(s)

Michael Leisch 3rd Medical Department with Hematology, Medical Oncology, Rheumatology and Infectiology, Paracelsus Medical University, 5020 Salzburg, Austria; (M.L.); (A.E.); (T.M.); (R.G.) Salzburg Cancer Research Institute (SCRI) Center for Clinical Cancer and Immunology Trials (CCCIT), Cancer Cluster Salzburg (CCS), 5020 Salzburg, Austria Austrian Group of Medical Tumor Therapy (AGMT) Study Group, 1140 Vienna, Austria; (M.P.); (R.S.); (S.H.); (H.S.); (M.G.); (M.S.-M.); (C.T.); (B.H.); (A.P.); (M.S.); (D.K.); (S.V.); (G.P.); (A.Z.); (S.M.-S.); (D.W.); (F.K.)
Michael Pfeilstöcker Austrian Group of Medical Tumor Therapy (AGMT) Study Group, 1140 Vienna, Austria; (M.P.); (R.S.); (S.H.); (H.S.); (M.G.); (M.S.-M.); (C.T.); (B.H.); (A.P.); (M.S.); (D.K.); (S.V.); (G.P.); (A.Z.); (S.M.-S.); (D.W.); (F.K.) 3rd Medical Department for Haematology and Oncology, Hanusch Hospital, 1140 Vienna, Austria
Reinhard Stauder Austrian Group of Medical Tumor Therapy (AGMT) Study Group, 1140 Vienna, Austria; (M.P.); (R.S.); (S.H.); (H.S.); (M.G.); (M.S.-M.); (C.T.); (B.H.); (A.P.); (M.S.); (D.K.); (S.V.); (G.P.); (A.Z.); (S.M.-S.); (D.W.); (F.K.) Department of Internal Medicine V, Innsbruck Medical University, 6020 Innsbruck, Austria
Sonja Heibl Austrian Group of Medical Tumor Therapy (AGMT) Study Group, 1140 Vienna, Austria; (M.P.); (R.S.); (S.H.); (H.S.); (M.G.); (M.S.-M.); (C.T.); (B.H.); (A.P.); (M.S.); (D.K.); (S.V.); (G.P.); (A.Z.); (S.M.-S.); (D.W.); (F.K.) 4th Medical Department of Internal Medicine, Hematology, Internistic Oncology and Palliative Medicine, Klinikum Wels-Grieskirchen GmbH, 4600 Wels, Austria
Heinz Sill Austrian Group of Medical Tumor Therapy (AGMT) Study Group, 1140 Vienna, Austria; (M.P.); (R.S.); (S.H.); (H.S.); (M.G.); (M.S.-M.); (C.T.); (B.H.); (A.P.); (M.S.); (D.K.); (S.V.); (G.P.); (A.Z.); (S.M.-S.); (D.W.); (F.K.) Division of Hematology, Medical University of Graz, 8036 Graz, Austria
Michael Girschikofsky Austrian Group of Medical Tumor Therapy (AGMT) Study Group, 1140 Vienna, Austria; (M.P.); (R.S.); (S.H.); (H.S.); (M.G.); (M.S.-M.); (C.T.); (B.H.); (A.P.); (M.S.); (D.K.); (S.V.); (G.P.); (A.Z.); (S.M.-S.); (D.W.); (F.K.) 1st Medical Department, Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Ordensklinikum Linz GmbH Elisabethinen, 4020 Linz, Austria
Margarete Stampfl-Mattersberger Austrian Group of Medical Tumor Therapy (AGMT) Study Group, 1140 Vienna, Austria; (M.P.); (R.S.); (S.H.); (H.S.); (M.G.); (M.S.-M.); (C.T.); (B.H.); (A.P.); (M.S.); (D.K.); (S.V.); (G.P.); (A.Z.); (S.M.-S.); (D.W.); (F.K.) Department of Internal Medicine 2, Klinik Donaustadt, 1220 Vienna, Austria
Christoph Tinchon Austrian Group of Medical Tumor Therapy (AGMT) Study Group, 1140 Vienna, Austria; (M.P.); (R.S.); (S.H.); (H.S.); (M.G.); (M.S.-M.); (C.T.); (B.H.); (A.P.); (M.S.); (D.K.); (S.V.); (G.P.); (A.Z.); (S.M.-S.); (D.W.); (F.K.) Department for Hemato-Oncology, LKH Hochsteiermark, 8700 Leoben, Austria
Bernd Hartmann Austrian Group of Medical Tumor Therapy (AGMT) Study Group, 1140 Vienna, Austria; (M.P.); (R.S.); (S.H.); (H.S.); (M.G.); (M.S.-M.); (C.T.); (B.H.); (A.P.); (M.S.); (D.K.); (S.V.); (G.P.); (A.Z.); (S.M.-S.); (D.W.); (F.K.) Department of Internal Medicine, Landeskrankenhaus Feldkirch, 6800 Feldkirch, Austria
Andreas Petzer Austrian Group of Medical Tumor Therapy (AGMT) Study Group, 1140 Vienna, Austria; (M.P.); (R.S.); (S.H.); (H.S.); (M.G.); (M.S.-M.); (C.T.); (B.H.); (A.P.); (M.S.); (D.K.); (S.V.); (G.P.); (A.Z.); (S.M.-S.); (D.W.); (F.K.) Medical Oncology and Hematology, Internal Medicine I, Ordensklinikum Linz GmbH Barmherzige Schwestern, 4020 Linz, Austria
Martin Schreder Austrian Group of Medical Tumor Therapy (AGMT) Study Group, 1140 Vienna, Austria; (M.P.); (R.S.); (S.H.); (H.S.); (M.G.); (M.S.-M.); (C.T.); (B.H.); (A.P.); (M.S.); (D.K.); (S.V.); (G.P.); (A.Z.); (S.M.-S.); (D.W.); (F.K.) 1st Department of Internal Medicine, Center for Oncology and Hematology, Klinik Ottakring, 1160 Vienna, Austria
David Kiesl Austrian Group of Medical Tumor Therapy (AGMT) Study Group, 1140 Vienna, Austria; (M.P.); (R.S.); (S.H.); (H.S.); (M.G.); (M.S.-M.); (C.T.); (B.H.); (A.P.); (M.S.); (D.K.); (S.V.); (G.P.); (A.Z.); (S.M.-S.); (D.W.); (F.K.) Department of Hematology and Medical Oncology, Kepleruniversitätsklinikum, 4020 Linz, Austria
Sonia Vallet Austrian Group of Medical Tumor Therapy (AGMT) Study Group, 1140 Vienna, Austria; (M.P.); (R.S.); (S.H.); (H.S.); (M.G.); (M.S.-M.); (C.T.); (B.H.); (A.P.); (M.S.); (D.K.); (S.V.); (G.P.); (A.Z.); (S.M.-S.); (D.W.); (F.K.) Department of Internal Medicine 2, University Hospital Krems, Karl Landsteiner Private University of Health Sciences, 3500 Krems, Austria
Alexander Egle 3rd Medical Department with Hematology, Medical Oncology, Rheumatology and Infectiology, Paracelsus Medical University, 5020 Salzburg, Austria; (M.L.); (A.E.); (T.M.); (R.G.) Salzburg Cancer Research Institute (SCRI) Center for Clinical Cancer and Immunology Trials (CCCIT), Cancer Cluster Salzburg (CCS), 5020 Salzburg, Austria Austrian Group of Medical Tumor Therapy (AGMT) Study Group, 1140 Vienna, Austria; (M.P.); (R.S.); (S.H.); (H.S.); (M.G.); (M.S.-M.); (C.T.); (B.H.); (A.P.); (M.S.); (D.K.); (S.V.); (G.P.); (A.Z.); (S.M.-S.); (D.W.); (F.K.)
Thomas Melchardt 3rd Medical Department with Hematology, Medical Oncology, Rheumatology and Infectiology, Paracelsus Medical University, 5020 Salzburg, Austria; (M.L.); (A.E.); (T.M.); (R.G.) Salzburg Cancer Research Institute (SCRI) Center for Clinical Cancer and Immunology Trials (CCCIT), Cancer Cluster Salzburg (CCS), 5020 Salzburg, Austria Austrian Group of Medical Tumor Therapy (AGMT) Study Group, 1140 Vienna, Austria; (M.P.); (R.S.); (S.H.); (H.S.); (M.G.); (M.S.-M.); (C.T.); (B.H.); (A.P.); (M.S.); (D.K.); (S.V.); (G.P.); (A.Z.); (S.M.-S.); (D.W.); (F.K.)
Gudrun Piringer Austrian Group of Medical Tumor Therapy (AGMT) Study Group, 1140 Vienna, Austria; (M.P.); (R.S.); (S.H.); (H.S.); (M.G.); (M.S.-M.); (C.T.); (B.H.); (A.P.); (M.S.); (D.K.); (S.V.); (G.P.); (A.Z.); (S.M.-S.); (D.W.); (F.K.) 4th Medical Department of Internal Medicine, Hematology, Internistic Oncology and Palliative Medicine, Klinikum Wels-Grieskirchen GmbH, 4600 Wels, Austria
Armin Zebisch Austrian Group of Medical Tumor Therapy (AGMT) Study Group, 1140 Vienna, Austria; (M.P.); (R.S.); (S.H.); (H.S.); (M.G.); (M.S.-M.); (C.T.); (B.H.); (A.P.); (M.S.); (D.K.); (S.V.); (G.P.); (A.Z.); (S.M.-S.); (D.W.); (F.K.) Division of Hematology, Medical University of Graz, 8036 Graz, Austria Otto Loewi Research Center for Vascular Biology, Immunology and Inflammation, Division of Pharmacology, Medical University of Graz, 8036 Graz, Austria
Sigrid Machherndl-Spandl Austrian Group of Medical Tumor Therapy (AGMT) Study Group, 1140 Vienna, Austria; (M.P.); (R.S.); (S.H.); (H.S.); (M.G.); (M.S.-M.); (C.T.); (B.H.); (A.P.); (M.S.); (D.K.); (S.V.); (G.P.); (A.Z.); (S.M.-S.); (D.W.); (F.K.) 1st Medical Department, Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Ordensklinikum Linz GmbH Elisabethinen, 4020 Linz, Austria
Dominik Wolf Austrian Group of Medical Tumor Therapy (AGMT) Study Group, 1140 Vienna, Austria; (M.P.); (R.S.); (S.H.); (H.S.); (M.G.); (M.S.-M.); (C.T.); (B.H.); (A.P.); (M.S.); (D.K.); (S.V.); (G.P.); (A.Z.); (S.M.-S.); (D.W.); (F.K.) Department of Internal Medicine V, Innsbruck Medical University, 6020 Innsbruck, Austria
Felix Keil Austrian Group of Medical Tumor Therapy (AGMT) Study Group, 1140 Vienna, Austria; (M.P.); (R.S.); (S.H.); (H.S.); (M.G.); (M.S.-M.); (C.T.); (B.H.); (A.P.); (M.S.); (D.K.); (S.V.); (G.P.); (A.Z.); (S.M.-S.); (D.W.); (F.K.) 3rd Medical Department for Haematology and Oncology, Hanusch Hospital, 1140 Vienna, Austria
Manuel Drost Assign Data Management and Biostatistics GmbH, 6020 Innsbruck, Austria;
Richard Greil 3rd Medical Department with Hematology, Medical Oncology, Rheumatology and Infectiology, Paracelsus Medical University, 5020 Salzburg, Austria; (M.L.); (A.E.); (T.M.); (R.G.) Salzburg Cancer Research Institute (SCRI) Center for Clinical Cancer and Immunology Trials (CCCIT), Cancer Cluster Salzburg (CCS), 5020 Salzburg, Austria Austrian Group of Medical Tumor Therapy (AGMT) Study Group, 1140 Vienna, Austria; (M.P.); (R.S.); (S.H.); (H.S.); (M.G.); (M.S.-M.); (C.T.); (B.H.); (A.P.); (M.S.); (D.K.); (S.V.); (G.P.); (A.Z.); (S.M.-S.); (D.W.); (F.K.)
Lisa Pleyer 3rd Medical Department with Hematology, Medical Oncology, Rheumatology and Infectiology, Paracelsus Medical University, 5020 Salzburg, Austria; (M.L.); (A.E.); (T.M.); (R.G.) Salzburg Cancer Research Institute (SCRI) Center for Clinical Cancer and Immunology Trials (CCCIT), Cancer Cluster Salzburg (CCS), 5020 Salzburg, Austria Austrian Group of Medical Tumor Therapy (AGMT) Study Group, 1140 Vienna, Austria; (M.P.); (R.S.); (S.H.); (H.S.); (M.G.); (M.S.-M.); (C.T.); (B.H.); (A.P.); (M.S.); (D.K.); (S.V.); (G.P.); (A.Z.); (S.M.-S.); (D.W.); (F.K.) Correspondence:

Collapse

Bouchla A, Thomopoulos TP, Papageorgiou SG, Apostolopoulou C, Loucari C, Mpazani E, Pappa V. Predicting outcome in higher-risk myelodysplastic syndrome patients treated with azacitidine. Epigenomics 2021;13:1129-1143. [PMID: 34291653 DOI: 10.2217/epi-2021-0124] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open

Papageorgiou SG, Kotsianidis I, Bouchla A, Symeonidis A, Galanopoulos A, Viniou NA, Hatzimichael E, Vassilakopoulos TP, Gogos D, Megalakaki A, Zikos P, Diamantopoulos P, Kourakli A, Giannoulia P, Papoutselis M, Poulakidas E, Arapaki M, Vardi A, Anagnostopoulos A, Mparmparousi D, Papaioannou M, Bouronikou E, Dimou M, Papadaki H, Panayiotidis P, Pappa V. Serum ferritin and ECOG performance status predict the response and improve the prognostic value of IPSS or IPSS-R in patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia treated with 5-azacytidine: a retrospective analysis of the Hellenic national registry of myelodysplastic and hypoplastic syndromes. Ther Adv Hematol 2020;11:2040620720966121. [PMID: 33343854 PMCID: PMC7727043 DOI: 10.1177/2040620720966121] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2020] [Accepted: 09/23/2020] [Indexed: 11/16/2022] Open

Affiliation(s)

Sotirios G Papageorgiou Consultant of Hematology, Second Department of Internal Medicine and Research Unit, University General Hospital "Attikon", 1 Rimini St., Haidari, Athens, 12462, Greece
Ioannis Kotsianidis Department of Hematology, Democritus University of Thrace Medical School, University Hospital of Alexandroupolis, Alexandroupolis, Greece
Anthi Bouchla Second Department of Internal Medicine and Research Unit, University General Hospital "Attikon", Haidari, Athens, Greece
Argyris Symeonidis The Hellenic (Greek) MDS Study Group, Greece
Athanasios Galanopoulos The Hellenic (Greek) MDS Study Group, Greece
Nora-Athina Viniou The Hellenic (Greek) MDS Study Group, Greece
Eleftheria Hatzimichael University Hospital of Ioannina, Ioannina, Greece
Theodoros P Vassilakopoulos Department of Hematology, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece
Dimitrios Gogos General Hospital "Bostanio" Mytilini, Greece
Aikaterini Megalakaki Department of Hematology, "Metaxa" Piraeus Cancer Hospital, Piraeus, Greece
Panagiotis Zikos General Hospital of Patras "Agios Andreas", Patras, Greece
Panagiotis Diamantopoulos Department of Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece
Alexandra Kourakli General University Hospital of Patras, Rio Patron, Patras, Greece
Panagiota Giannoulia Department of Hematology, "Evangelismos" Hospital, Athens, Greece
Menelaos Papoutselis Department of Hematology, Democritus University of Thrace Medical School, University Hospital of Alexandroupolis, Alexandroupolis, Greece
Elias Poulakidas "401" Army General Hospital of Athens, Mesogeion and Kanellopoulou 1, Athens, Greece
Maria Arapaki Department of Hematology, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece
Anna Vardi Hematology Department, General Hospital of Thessaloniki "George Papanikolaou", Thessaloniki, Greece
Achilles Anagnostopoulos Hematology Department, General Hospital of Thessaloniki "George Papanikolaou", Thessaloniki, Greece
Despoina Mparmparousi Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
Maria Papaioannou Hematology Department, University General Hospital of Thessaloniki AHEPA, Thessaloniki, Greece
Eleni Bouronikou University General Hospital of Larissa, Mezourlo, Larissa, Greece
Maria Dimou First Propaedeutic Department of Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece
Helen Papadaki University General Hospital of Heraklion, Voutes, Heraklion, Greece
Panayiotis Panayiotidis First Propaedeutic Department of Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece
Vasiliki Pappa Second Department of Internal Medicine and Research Unit, University General Hospital "Attikon", Haidari, Athens, Greece

Collapse

Cai L, Zhao X, Ai L, Wang H. Role Of TP53 mutations in predicting the clinical efficacy of hypomethylating therapy in patients with myelodysplastic syndrome and related neoplasms: a systematic review and meta-analysis. Clin Exp Med 2020;20:361-371. [PMID: 32613269 DOI: 10.1007/s10238-020-00641-4] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2020] [Accepted: 06/16/2020] [Indexed: 02/07/2023]

Papageorgiou SG, Kontos CK, Kotsianidis I, Vasilatou D, Symeonidis A, Galanopoulos A, Bouchla A, Hatzimichael E, Repousis P, Zikos P, Viniou NA, Poulakidas E, Vassilakopoulos TP, Diamantopoulos P, Diamantopoulos MA, Mparmparousi D, Bouronikou E, Papadaki H, Panayiotidis P, Pappa V. The outcome of patients with high-risk MDS achieving stable disease after treatment with 5-azacytidine: A retrospective analysis of the Hellenic (Greek) MDS Study Group. Hematol Oncol 2018;36:693-700. [DOI: 10.1002/hon.2551] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2018] [Accepted: 08/13/2018] [Indexed: 11/10/2022]

Affiliation(s)

Sotirios G. Papageorgiou Second Department of Internal Medicine and Research Unit; University General Hospital “Attikon”; Athens Greece
Christos K. Kontos Department of Biochemistry and Molecular Biology; University of Athens; Athens Greece
Ioannis Kotsianidis Department of Hematology, Democritus University of Thrace Medical School; University Hospital of Alexandroupolis; Alexandroupolis Greece The Hellenic (Greek) MDS Study Group; Athens Greece
Diamantina Vasilatou Second Department of Internal Medicine and Research Unit; University General Hospital “Attikon”; Athens Greece
Argyris Symeonidis The Hellenic (Greek) MDS Study Group; Athens Greece General University Hospital of Patras; Patras Greece
Athanasios Galanopoulos The Hellenic (Greek) MDS Study Group; Athens Greece General Hospital of Athens ‘G. Gennimatas’; Athens Greece
Anthi Bouchla Second Department of Internal Medicine and Research Unit; University General Hospital “Attikon”; Athens Greece
Eleftheria Hatzimichael University Hospital of Ioannina; Ioannina Greece
Panagiotis Repousis Department of Hematology; ‘Metaxa’ Piraeus Cancer Hospital; Piraeus Greece
Panagiotis Zikos General Hospital of Patras ‘Agios Andreas’; Patras Greece
Nora-Athina Viniou The Hellenic (Greek) MDS Study Group; Athens Greece First Department of Internal Medicine; National and Kapodistrian University of Athens; Athens Greece
Elias Poulakidas ‘401’ Army General Hospital of Athens; Athens Greece
Theodoros P. Vassilakopoulos Department of Haematology; National and Kapodistrian University of Athens, Laikon General Hospital; Athens Greece
Panagiotis Diamantopoulos First Department of Internal Medicine; National and Kapodistrian University of Athens; Athens Greece
Marios A. Diamantopoulos Department of Biochemistry and Molecular Biology; University of Athens; Athens Greece
Despoina Mparmparousi Department of Clinical Therapeutics; National and Kapodistrian University of Athens, School of Medicine; Athens Greece
Eleni Bouronikou University General Hospital of Larissa; Larissa Greece
Helen Papadaki University General Hospital of Heraklion; Heraklion Greece
Panayiotis Panayiotidis First Propaedeutic Department of Internal Medicine; National and Kapodistrian University of Athens; Athens Greece
Vasiliki Pappa Second Department of Internal Medicine and Research Unit; University General Hospital “Attikon”; Athens Greece The Hellenic (Greek) MDS Study Group; Athens Greece

Collapse

Papageorgiou SG, Vasilatou D, Kontos CK, Kotsianidis I, Symeonidis A, Galanopoulos AG, Hatzimichael E, Megalakaki A, Poulakidas E, Diamantopoulos P, Vassilakopoulos TP, Zikos P, Papadaki H, Mparmparousi D, Bouronikou E, Panayiotidis P, Viniou NA, Pappa V. The prognostic value of monosomal karyotype (MK) in higher-risk patients with myelodysplastic syndromes treated with 5-Azacitidine: A retrospective analysis of the Hellenic (Greek) Myelodysplastic syndromes Study Group. Am J Hematol 2018;93:895-901. [PMID: 29659040 DOI: 10.1002/ajh.25111] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2018] [Revised: 04/05/2018] [Accepted: 04/06/2018] [Indexed: 11/08/2022]

Affiliation(s)

Sotirios G. Papageorgiou Second Department of Internal Medicine and Research Unit; University General Hospital “Attikon”, 1 Rimini St., Haidari; Athens 12462 Greece
Diamantina Vasilatou Second Department of Internal Medicine and Research Unit; University General Hospital “Attikon”, 1 Rimini St., Haidari; Athens 12462 Greece
Christos K. Kontos Department of Biochemistry and Molecular Biology; National and Kapodistrian University of Athens, Panepistimiopolis; Athens 15701 Greece
Ioannis Kotsianidis Department of Hematology; Democritus University of Thrace Medical School, University Hospital of Alexandroupolis; Alexandroupolis Greece The Hellenic (Greek) MDS Study Group
Argiris Symeonidis The Hellenic (Greek) MDS Study Group General University Hospital of Patras, Rio Patron; Patras 26500 Greece
Athanasios G. Galanopoulos The Hellenic (Greek) MDS Study Group General Hospital of Athens “G. Gennimatas”, Mesogeion 154; Athens 11527 Greece
Eleftheria Hatzimichael University Hospital of Ioannina; Ioannina 45100 Greece
Aekaterini Megalakaki Department of Hematology; “Metaxa” Piraeus Cancer Hospital; Piraeus Greece
Elias Poulakidas Mesogeion and Kanellopoulou 1; “401” Army General Hospital of Athens; Athens 11525 Greece
Panagiotis Diamantopoulos 1 Department of Internal Medicine; National and Kapodistrian University of Athens; Athens Greece
Theodoros P. Vassilakopoulos Department of Haematology; National and Kapodistrian University of Athens, Laikon General Hospital; Athens Greece
Panagiotis Zikos General Hospital of Patras “Agios Andreas”, Tsertidou 1; Patras 26335 Greece
Helen Papadaki University General Hospital of Heraklion, Voutes; Heraklion 71110 Greece
Despoina Mparmparousi Department of Clinical Therapeutics; National and Kapodistrian University of Athens, School of Medicine; Athens Greece
Eleni Bouronikou University General Hospital of Larissa, Mezourlo; Larissa 41110 Greece
Panayiotis Panayiotidis 1 Propaedeutic Department of Internal Medicine; National and Kapodistrian University of Athens; Athens Greece
Nora-Athina Viniou The Hellenic (Greek) MDS Study Group Mesogeion and Kanellopoulou 1; “401” Army General Hospital of Athens; Athens 11525 Greece
Vassiliki Pappa Second Department of Internal Medicine and Research Unit; University General Hospital “Attikon”, 1 Rimini St., Haidari; Athens 12462 Greece The Hellenic (Greek) MDS Study Group

Collapse

Kourtis A, Adamopoulos PG, Papalois A, Iliopoulos DC, Babis GC, Scorilas A. Quantitative analysis and study of the mRNA expression levels of apoptotic genes BCL2, BAX and BCL2L12 in the articular cartilage of an animal model of osteoarthritis. ANNALS OF TRANSLATIONAL MEDICINE 2018;6:243. [PMID: 30069445 DOI: 10.21037/atm.2018.05.47] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]

Adamopoulos PG, Theodoropoulou MC, Scorilas A. Alternative Splicing Detection Tool-a novel PERL algorithm for sensitive detection of splicing events, based on next-generation sequencing data analysis. ANNALS OF TRANSLATIONAL MEDICINE 2018;6:244. [PMID: 30069446 DOI: 10.21037/atm.2018.06.32] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]

Diamantopoulos MA, Tsiakanikas P, Scorilas A. Non-coding RNAs: the riddle of the transcriptome and their perspectives in cancer. ANNALS OF TRANSLATIONAL MEDICINE 2018;6:241. [PMID: 30069443 DOI: 10.21037/atm.2018.06.10] [Citation(s) in RCA: 78] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]